- 貨號 Cat. No.
- S2683
- 規格 Size
- 5~200mg
- 品牌 Brand
- Selleckchem
Description
CHIR-124
CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM. It shows 2,000-fold selectivity against Chk2, 500- to 5,000-fold less activity against CDK2/4 and Cdc2.
Size |
Price |
Stock |
Quantity |
|
|---|
10mM/1mLIn DMSO |
USD 168 |
In stock |
0
1
2
3
4
5
6
7
8
9
10
|
2mg |
USD 88 |
In stock |
0
1
2
3
4
5
6
7
8
9
10
|
5mg |
USD 151 |
In stock |
0
1
2
3
4
5
6
7
8
9
10
|
25mg |
USD 466 |
In stock |
0
1
2
3
4
5
6
7
8
9
10
|
100mg |
USD 1222 |
In stock |
0
1
2
3
4
5
6
7
8
9
10
|
|
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
Biological Activity
Description |
CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM. It shows 2,000-fold selectivity against Chk2, 500- to 5,000-fold less activity against CDK2/4 and Cdc2. |
|---|
Targets |
Chk1 |
|
|
|
|
|
|---|
IC50 |
0.3 nM [1] |
|
|
|
|
|
|---|
In vitro |
CHIR-124 is a quinolone-based small molecule that is structurally unrelated to other known inhibitors of Chk1. CHIR-124 interacts synergistically with topoisomerase poisons (e.g., Camptothecin or SN-38) in causing growth inhibition in a variety of cancer cell lines, including breast carcinoma (MDA-MB-231 and MDA-MB-435) and colon carcinoma (SW-620 and Colo205), all of which contains the mutant p53 gene. CHIR-124 abrogates the SN-38-induced S and G2-M checkpoints and potentiates apoptosis in MDA-MD-435 breast cancer cells. The abrogation of the G2-Mcheckpoint and induction of apoptosis by CHIR-124 are enhanced by the loss of p53. [1]CHIR-124 also potently targets other kinases such as PDGFR and Flt3 with IC50 of 6.6 nM and 5.8 nM, respectively. [2] |
|---|
In vivo |
CHIR-124 potentiates the growth inhibitory effects of Irinotecan by abrogating the G2-M checkpoint and increasing tumor apoptosis in an orthotopic breast cancer xenograft model. |
|---|
Features |
|
|---|
Protocol(Only for Reference)
Kinase Assay: [1]
Chk1 Assay |
For the Chk1 assay, the kinase domain is expressed in Sf9 insect cells, and a biotinylated cdc25c peptide containing the consensus Chk1/Chk2 phosphorylation site (*)(biotin-[AHX]SGSGS*GLYRSPSMP-ENLNRPR[CONH2]) is used as the substrate. A dilution series of CHIR-124 is mixed with a kinase reaction buffer containing a final concentration of 30 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 2 mM DTT, 4 mM EDTA, 25 mMβ-glycerophosphate, 5 mM MnCl2, 0.01% bovine serum albumin, 1.35 nM CHK1 kinase domain, 0.5 μM peptide substrate, and 1 AM unlabeled ATP, plus 5 nM 33Pγ-labeled ATP (specific activity = 2,000 Ci/mmol). Reactions and detection of the phosphate transfer are carried out by a radioactive method. Reactions are incubated at room temperature for 1 to 4 hours and the phosphorylated peptide captured on streptavidin-coated microtiter plates containing stop reaction buffer (25 mM EDTA [ethylenediaminetetraacetic acid], 50 mMHEPES, pH 7.5). Phosphorylated peptide is measured with the DELFIA TRF system using a Europium-labeled anti-phosphotyrosine antibody PT66. The concentration of CHIR-124 for IC50 is calculated using nonlinear regression with XL-Fit data analysis software. |
|---|
Cell Assay: [1]
Cell lines |
MDA-MB-231, MDA-MB-435, SW-620, and COLO 205 cells |
|---|
Concentrations |
0-2350 nM, dependent on cell types |
|---|
Incubation Time |
48 hours |
|---|
Method |
MDA-MB-231, MDA-MB-435, SW-620, and COLO 205 cells in log-phase are plated into 96-well microplates. CHIR-124 is serially diluted in the presence of six different concentrations of Camptothecin or 0 nM camptothecin. Camptothecin is also serially diluted in the absence of CHIR-124. CHIR-124 is added to cells in 96-well dishes and incubated at 37 °C for 48 hours. Each treatment condition is done in triplicate. Cell proliferation is monitored by the 3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS), inner salt assay. MTS inner salt is added to the microplates, which are incubated for another 3 hours, and absorbance at 490 nm is read on a plate reader. The concentrations of each drug in the combinations required to produce 50% inhibition are plotted to generate the isoboles. Isobologram analysis of drug interaction is based the equation of Loewe additivity (1= D A /IC50, A + DB/IC50, B), where IC50, A and IC50, B are the concentrations of drugs to result in 50% inhibition for each drug alone, and DA and DB are concentrations of each drug in the combination that yield 50% overall inhibition. A diagonal line indicating Loewe additivity is included in each graph. Data points that fall below the line indicate synergy, whereas those that fall above the line will indicate antagonism |
|---|
Animal Study: [1]
Animal Models |
MDA-MB-435 cells are implanted in the mammary fat pad of 8- to 10-week-old female immunodeficient mice. |
|---|
Dosages |
10 mg/kg or 20 mg/kg |
|---|
Administration |
CHIR-124 is given orally four times daily × 6 on days 2 to 7 in captisol. |
|---|
Solubility |
1% DMSO/30% polyethylene glycol/1% Tween 80, 30 mg/mL |
|---|
1
References
Download CHIR-124 SDF
Molecular Weight (MW) |
419.91 |
|---|
Formula |
C23H22ClN5O
|
|---|
CAS No. |
405168-58-3 |
|---|
Storage |
3 years -20℃Powder |
|---|
6 months-80℃in DMSO |
Syonnyms |
N/A |
|---|
Solubility (25°C) * |
In vitro |
DMSO |
7 mg/mL (16 mM) |
|---|
Water |
<1 mg/mL (<1 mM) |
Ethanol |
<1 mg/mL (<1 mM) |
In vivo |
1% DMSO/30% polyethylene glycol/1% Tween 80, |
30 mg/mL |
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Chemical Name |
(S)-3-(1H-benzo[d]imidazol-2-yl)-6-chloro-4-(quinuclidin-3-ylamino)quinolin-2(1H)-one |
|---|
Stock Solution (1ml DMSO) |
1mM |
10mM |
20mM |
30mM |
|---|
Mass(mg) |
0.41991 |
4.1991 |
- |
- |
Product Citations (1)
詢價 / 洽詢此產品
